MediciNova Announces Presentation Regarding Clinical Trial of MN-166 in ALS at California ALS Pac10 and Research Network Meeting

MediciNova, Inc., MNOV announced that Dr. Yuichi Iwaki, President and CEO, has accepted an invitation to make a presentation regarding the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) at the 6th Annual California ALS Pac10 and Research Network Meeting which will be held at the Sanford Consortium for Regenerative Medicine, UCSD, La Jolla, California. Presentation details are as follows: Session Date and Time:  January 8th, 2016, 10:30 AM PST Location:  Sanford Consortium for Regenerative Medicine, UCSD, La Jolla, California Title: Ibudilast (MN-166), Neuro Protective and Anti-Neuroinflammatory Compound, for ALS About the ALS Trial MediciNova, in collaboration with Dr. Benjamin Rix Brooks, Director, Carolinas Healthcare System's Neuromuscular/ALS-MDA Center, is currently evaluating MN-166 (ibudilast) in both early and advanced stage ALS patients.  This ongoing trial is a randomized, double-blind, placebo-controlled study which includes a six-month treatment period followed by a six-month open-label extension. The study is evaluating several efficacy endpoints including functional activity (ALSFRS-R), respiratory function and muscle strength See full press release